Cardiac function in mice lacking the glucagon-like peptide-1 receptor

被引:159
|
作者
Gros, R
You, XM
Baggio, LL
Kabir, MG
Sadi, AM
Mungrue, IN
Parker, TG
Huang, QL
Drucker, DJ
Husain, M
机构
[1] Toronto Gen Hosp, Res Inst, Div Cellular & Mol Biol, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Toronto, ON M5G 2C4, Canada
[3] Univ Toronto, Toronto Gen Hosp, Dept Med, Banting & Best Diabet Ctr, Toronto, ON M5G 2C4, Canada
关键词
D O I
10.1210/en.2003-0007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glucagon-like peptide-1 (GLP-1) acts via its G protein-coupled receptor (GLP-1R) to regulate blood glucose. Although the GLP-1R is widely expressed in peripheral tissues, including the heart, and exogenous GLP-1 administration increases heart rate and blood pressure in rodents, the physiological importance of GLP-1R action in the cardiovascular system remains unclear. We now show that 2-month-old mice with genetic deletion of the GLP-1R (GLP-1R(-/-)) exhibit reduced resting heart rate and elevated left ventricular (LV) end diastolic pressure compared with CD-1 wild-type controls. At the age of 5 months, echocardiography and histology demonstrate increased LV thickness in GLP-1R(-/-) mice. Although baseline hemodynamic parameters of GLP-1R(-/-) did not differ significantly from those of wild type, GLP-1R(-/-) mice displayed impaired LV contractility and diastolic function after insulin administration. The defective cardiovascular response to insulin was not attributable to a generalized defect in the stress response, because GLP-1R(-/-) mice responded appropriately to insulin with increased c-fos expression in the hypothalamus and increased circulating levels of glucagon and epinephrine. Furthermore, LV contractility after exogenous epinephrine infusion was also reduced in GLP-1R(-/-) mice. These findings provide new evidence implicating an essential role for GLP-1R in the control of murine cardiac structure and function in vivo.
引用
收藏
页码:2242 / 2252
页数:11
相关论文
共 50 条
  • [41] Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
    Chen, J.
    Cooper, M. E.
    Coughlan, M. T.
    DIABETES & METABOLISM, 2025, 51 (03)
  • [42] Perioperative Implications of Glucagon-like Peptide-1 Receptor Agonists
    Wolfe, Rachel C.
    JOURNAL OF PERIANESTHESIA NURSING, 2024, 39 (06) : 1108 - 1110
  • [43] Glucagon-like peptide-1 receptor expression in the human eye
    Hebsgaard, Josephine B.
    Pyke, Charles
    Yildirim, Emre
    Knudsen, Lotte B.
    Heegaard, Steffen
    Kvist, Peter H.
    DIABETES OBESITY & METABOLISM, 2018, 20 (09): : 2304 - 2308
  • [44] Charaterization of binding determinants of glucagon-like peptide-1 receptor
    Xiao, Q
    Jeng, W
    Wheeler, MB
    DIABETES, 2000, 49 : A228 - A228
  • [45] ANTIDIABETOGENIC ACTION OF TRUNCATED GLUCAGON-LIKE PEPTIDE-1 IN MICE
    AHREN, B
    ENDOCRINE, 1995, 3 (05): : 367 - 369
  • [46] Expression of the Glucagon-Like Peptide-1 Receptor in Psoriasis Plaques
    Faurschou, Annesofie
    Pedersen, Jens
    Gyldenlove, Mette
    Poulsen, Sten S.
    Holst, Jens J.
    Zachariae, Claus
    Skov, Lone
    Vilsboll, Tina
    Knop, Filip K.
    DIABETES, 2012, 61 : A704 - A705
  • [47] Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity
    Jensterle, Mojca
    Janez, Andrej
    HORMONE RESEARCH IN PAEDIATRICS, 2023, 96 (06): : 599 - 608
  • [48] Evaluating the glucagon-like peptide-1 receptor in managing asthma
    Wu, Ashley Y.
    Cahill, Katherine N.
    Toki, Shinji
    Peebles, R. Stokes, Jr.
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 22 (01) : 36 - 41
  • [49] Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
    During, MJ
    Cao, L
    Zuzga, DS
    Francis, JS
    Fitzsimons, HL
    Jiao, XY
    Bland, RJ
    Klugmann, M
    Banks, WA
    Drucker, DJ
    Haile, CN
    NATURE MEDICINE, 2003, 9 (09) : 1173 - 1179
  • [50] Weighing in on glucagon-like peptide-1 receptor agonists in dermatology
    Heymann, Warren R.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (01) : 29 - 30